^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Riabni (rituximab-arrx) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    12/17/2020
    Excerpt:
    RIABNI (rituximab-arrx) is a CD20-directed cytolytic antibody indicated for the treatment of...Adult patients with Chronic Lymphocytic Leukemia (CLL)...Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
    Secondary therapy:
    cyclophosphamide + fludarabine IV